Comparative effectiveness and safety of robotic versus laparoscopic liver resection for benign liver diseases: a systematic review and meta-analysis.

BMC GastroenterolSep 12, 2026 (epub)
Clinical ResearchGeneral SurgeryGastroenterologyOpen access

Guo-Wang Li, Jing Li, Qiang Kang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness and safety of robotic liver resection (RLR) versus laparoscopic liver resection (LLR) for benign liver diseases, analyzing data from nine retrospective studies involving 790 patients. RLR demonstrated significant advantages, including a shorter operative time by 36.24 minutes and lower intraoperative blood loss by 55.66 mL compared to LLR.

Key findings

  • RLR was associated with a shorter setup-excluded operative time of 36.24 minutes.
  • Intraoperative blood loss was lower with RLR by 55.66 mL.
  • The conversion rate to open surgery was significantly lower for RLR (RR = 0.27).
  • Postoperative hospital stay was shorter by 0.68 days with RLR.

Why it matters

Understanding the comparative effectiveness of RLR and LLR can guide surgical decision-making for benign liver diseases, potentially leading to improved patient outcomes and resource utilization in surgical settings.

What to keep in mind

All included studies were retrospective, which may limit the reliability of the findings.

Source

PubMed · PMID 42736538Free full text on PubMed Central

Published in BMC Gastroenterol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.